AURA

Aura Biosciences, Inc. AURA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-45.64M

Quarter to Jun 30

Free cash flow

$-32.52M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$677.30M total
TCG Crossover Management, LLC
$67.69MNew
SUVRETTA CAPITAL MANAGEMENT, LLC
$51.16M+64.8%
Frazier Life Sciences Management, L.P.
$50.41M+39.2%
Long Focus Capital Management, LLC
$36.35M+10.8%
BlackRock, Inc.
$33.42M+31.3%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$32.94M-4.9%
Caligan Partners LP
$30.52M+1769.9%
VANGUARD CAPITAL MANAGEMENT LLC
$29.11M+82.7%
FCPM III SERVICES B.V.
$28.78MNew
ORBIMED ADVISORS LLC
$23.67MNew
Medicxi Ventures Management (Jersey) Ltd
$21.58M0.0%
Nantahala Capital Management, LLC
$20.95M+39.4%
Jupiter Topco LLC
$17.79M--
RA CAPITAL MANAGEMENT, L.P.
$17.75MNew
BALYASNY ASSET MANAGEMENT L.P.
$16.72M+322.2%
FRANKLIN RESOURCES INC
$14.72M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$12.46M+33.9%
Redmile Group, LLC
$11.83MNew
EcoR1 Capital, LLC
$11.83MNew
Trails Edge Capital Partners, LP
$10.25MNew
Foresite Capital Management VI LLC
$9.47MNew
STATE STREET CORP
$8.68M+26.8%
Woodline Partners LP
$8.59MNew
Bellevue Group AG
$8.28MNew
Vivo Capital, LLC
$8.28MNew
See all 147 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AURA

Earnings Per Share

13fpro.ai/company/AURA

Loading ratio trend…

AURA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Aura Biosciences, Inc. (AURA): stock profile, AI score and financials

Aura Biosciences, Inc. (AURA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AURA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aura Biosciences, Inc. reports net income of $-45.6M, free cash flow of $-32.5M. Top institutional holders of AURA by reported 13-F value include TCG Crossover Management, SUVRETTA CAPITAL MANAGEMENT, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. AURA trades on the Nasdaq exchange and files with the SEC under CIK 1501796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aura Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1501796 →